Vincristine-induced Peripheral Neuropathy in Adult Survivors of Childhood and Adolescent Leukemia - Trial NCT05759052
Access comprehensive clinical trial information for NCT05759052 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Clermont-Ferrand and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 750 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University Hospital, Clermont-Ferrand
Timeline & Enrollment
N/A
Mar 01, 2023
Jul 31, 2025
Primary Outcome
Sensitive chemotherapy-induced peripheral neuropathy
Summary
Vincristine is a major anticancer agent in the management of hematological malignancies. One
 of the main side effects is chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a
 characteristic side effect of neurotoxic anticancer drugs. CIPN associated with vincristine
 is typically characterized by distal and symmetrical sensory symptoms (dysesthesia and
 paresthesia). Motor and vegetative symptoms can also be found. The prevalence of CIPN
 associated with vincristine during treatment ranges from 12 to 100% in children (depending on
 the endpoint).
 
 The aim of this cross-sectionnal study will be to explore the CIPN prevalence and severity in
 adult survivors of childhood leukemia and having been treated by vincristine.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05759052
Non-Device Trial